Study identifier:1033IC/0029
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes with Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, when used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
Breast Cancer
Phase 3
No
Anastrozole (Arimidex), Tamoxifen (Nolvadex), Nolvadex placebo, Arimidex placebo
Female
285
Interventional
45 Years +
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Arimidex 1mg + Nolvadex placebo | Drug: Anastrozole (Arimidex) 1mg, orally, once daily Other Name: Arimidex |
Active Comparator: 2 Arimidex placebo + Nolvadex 20mg | Drug: Tamoxifen (Nolvadex) 20mg, orally, once daily Other Name: Nolvadex |
Active Comparator: 3 Arimidex 1mg + Nolvadex 20mg | Drug: Anastrozole (Arimidex) 1mg, orally, once daily Other Name: Arimidex Drug: Tamoxifen (Nolvadex) 20mg, orally, once daily Other Name: Nolvadex |